Q1 2025 Earnings Call Transcript October 24, 2024 ResMed Inc. beats earnings expectations. Reported EPS is $2.2, expectations ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

2030 ambition to help more than 500 million people worldwide achieve their full health potential Showcases integration of intelligent products and solutions within the ResMed ecosystem ...

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from ...

The program enables physicians to request molgramostim for eligible aPAP patients in select geographies where the product is not commercially available and in compliance with local regulatory ...

The global positive air pressure devices market is poised for substantial growth, according to a new market research report ...

The 30 elderly residents of the Apap Institute residential home in Santa Venera are to be relocated to another elderly home in Bugibba, the Archdiocese of Malta said on Thursday. The Archdiocese ...

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...

Hello, and welcome to the Q1 fiscal year 2025 ResMed Earnings conference call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions) Please note this conference call is ...

No significant news for RMD in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...